Drugs / folinate calcium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05290116 | Jul 2022 → May 2023 | intrahepatic cholangiocarcinoma | Yunfei Yuan | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05400902 Background | May → Dec 2023 | intrahepatic cholangiocarcinoma | Binkui Li | Unknown | No outcome recorded |
| Phase 3 | NCT00660894 Comparator | Apr 2008 → Jun 2012 | colorectal cancer | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | folinate calcium | “Hepatic Arterial Infusion Chemotherapy: FOLFOX6 regimen was infused with chemotherapy drugs: oxaliplatin 130 mg/m2 infusion for 2 hours, folinate calcium 400 mg/m2 infusion for...” NCT05290116 ↗ |
| Route | Oral | “Patients receive tegafur-uracil(UFT) plus folinate calcium(leucovorin) orally every 8 hours for 21 days with a subsequent pause of 7 days.” NCT00660894 ↗ |